Blood DNA methylation levels at cg00574958–CPT1A have also been reported associated with reduced risk of metabolic diseases, including metabolic syndrome, hypertension, and T2D (Table 5) [25, 52, 53]. This evidence concerns the gene CPT1A and Other metabolic disease.